A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
– Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers ...
Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. The Food and Drug Administration (FDA) has approved Blincyto ® (blinatumomab) for the treatment of adult and pediatric patients 1 month ...
Merck & Co. Inc. is acquiring Curon Biopharmaceutical Ltd.’s bispecific antibody CN-201 that targets CD3 and CD19 for B-cell associated diseases, for up to $1.3 billion. Under the terms of the deal, ...
The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space. The future treatment landscape for ...
Title: ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback